Oncolytic Virotherapy as a Novel Strategy for Pancreatic Cancer

Pancreas

Volumn 28, Issue 3, 2004, Pages 326-329

  Sunamura, Makoto ^a   Hamada, Hirofumi ^b   Motoi, Fuyuhiko ^c   Oonuma, Masaru ^c   Abe, Hisashi ^c   Saitoh, Yukoh ^c   Hoshida, Toru ^c   Ottomo, Shigeru ^c   Omura, Noriyuki ^c   Matsuno, Seiki ^c  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c Graduate School of Medicine ^*

Author keywords

Gene therapy; RB; Replication selective adenovirus; TP53; Uracil phosphoribosyl transferase

Indexed keywords

ADENOVIRUS VECTOR; E1A PROTEIN; FLUOROURACIL; PROTEIN P53; RETINOBLASTOMA PROTEIN; URACIL PHOSPHORIBOSYLTRANSFERASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL CYCLE S PHASE; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BINDING; SCID MOUSE; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ANIMALS; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; MICE; MICE, SCID; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; VIRUS REPLICATION;

EID: 12144289313     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200404000-00022     Document Type: Article

References (27)

1. Duda DG, Sunamura M, Lozonschi L, et al. Direct in vitro evidence and in vivo analysis of the anti-angiogenesis effects of interleukin 12. Cancer Res. 2000;60:1111-1116.
2. Duda DG, Sunamura M, Lozonschi L, et al. Overexpression of the p53-inducible brain angiogenesis inhibitor 1 suppresses efficiently tumor angiogenesis. Br J Cancer. 2002;86:490-496.
3. Hoshida T, Sunamura M, Duda DG, et al. Gene Therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas. 2002;25:111-121.
4. Duda DG, Sunamura M, Lefter LP, et al. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene. 2003;22:6857-6864.
5. Greenblatt MS, Bennet WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
6. Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994;54:3025-3033.
7. Yatsuoka T, Sunamura M, Furukawa T, et al. Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6q/17p and 12q/18q in human pancreatic ductal adenocarcinoma. Am J Gastroenterol. 2000;95:2080-2085.
8. Chinnadurai G. Control of apoptosis by human adenoviruses. Semin Virol. 1998;8:399-408.
9. Ricciardi RP. Transformation and tumorigenesis mediated by the adenovirus E1A and E1B oncogenes. In: Barbanti-Brodano G, Bendienelli M, Friedman H, eds. DNA tumor viruses: oncogenic mechanisms. New York: Plenum Press; 1995:195-225.
10. Beck GR, Zerler BR, Moran E. Introduction to DNA tumor viruses: adenovirus, simian virus 40, and polyomavirus. In: McCance DJ. ed. Human tumor viruses. Washington, DC: American Society of Microbiology, 1998
11. Goldsmith KT, Curiel DT, Engler JA, et al. Trans complementation of an E1A-deleted adenovirus with codelivered E1A sequences to make recombinant adenovirus producer cells. Hum Gene Ther. 1994;5:1341-1348.
12. Dion LD, Goldsmith KT, Strong TV, et al. E1A RNA transcripts amplify adenovirus-mediated tumor reduction. Gene Ther. 1996;3:1021-1025.
13. Han JS, Qian D, Wicha MS, et al. A method of limited replication for the efficient in vivo delivery of adenovirus to cancer cells. Hum Gene Ther. 1998;9:1209-1216.
14. Motoi F, Sunamura M, Ding L, et al. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum Gene Ther. 2000;11:223-235.
15. Oonuma M, Sunamura M, Motoi F, et al. Gene therapy for intraperitoneally disseminated pancreatic cancers by Escherichia coli uracil phosphoribosiltransferase (UPRT) gene mediated by restricted replication-competent adenoviral vectors. Int J Cancer. 2002;102:51-59.
16. Arany Z, Newsome D, Oldread E, et al. A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature. 1995;374:81-84.
17. Eckner R, Ewen ME, Newsome D, et al. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein(p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev. 1994;8:869-884.
18. Arany Z, Huang L, Eckner R, et al. An essential role of p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci U S A. 1996;93:12969-12973.
19. Saito Y, Sunamura M, Motoi F, et al. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region (submitted).
20. Adams PD, Kaelin WG. Transcriptional control by E2F. Semin Cancer Biol. 1995;6:99-108.
21. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
22. Abe H, Motoi F, Sunamura M, et al. A double-mutated oncolytic adenovirus, AxdAdB-3, is a potential therapeutics for pancreatic cancers with abnormal genetic pathways (submitted).
23. Smith RR, Huebner RJ, Rowe WP, et al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 1956;9:1211-1218.
24. Bischoff JR, et al. Anadenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373-376.
25. Kirn D, Hermiston I, McCormick F. ONYX-105: clinical data are encouraging. Nat Med. 1998:4:1341-1342.
26. Hecht JR, Bedford R, Abbruzzese JL, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003;9:555-561.
27. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002;62:6070-6079.